Page 2 - Acrx News Today

AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) had its price target trimmed by HC Wainwright from $8.00 to $5.00 in a research note issued to investors on Monday, MarketBeat reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for AcelRx Pharmaceuticals’ FY2024 earnings at ($0.75) EPS, […]

AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) had its target price trimmed by HC Wainwright from $8.00 to $5.00 in a research report sent to investors on Monday morning, Marketbeat reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for AcelRx Pharmaceuticals’ FY2024 earnings at ($0.75) […]

AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Free Report) and Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings. Volatility & Risk AcelRx Pharmaceuticals has a […]

HC Wainwright upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) from a neutral rating to a buy rating in a research report sent to investors on Friday, Marketbeat.com reports. HC Wainwright currently has $8.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for AcelRx Pharmaceuticals’ Q1 2024 earnings at […]

HC Wainwright upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) from a neutral rating to a buy rating in a report released on Friday, MarketBeat Ratings reports. They currently have $8.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for AcelRx Pharmaceuticals’ Q1 2024 earnings at ($0.21) EPS, Q2 […]

AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Free Report) was upgraded by equities researchers at HC Wainwright from a “neutral” rating to a “buy” rating in a research report issued on Friday, FlyOnTheWall reports. Separately, StockNews.com initiated coverage on shares of AcelRx Pharmaceuticals in a research note on Thursday. They set a “sell” rating for the company. […]

StockNews.com began coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a research report released on Thursday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock. AcelRx Pharmaceuticals Trading Up 4.3 % NASDAQ ACRX opened at $0.84 on Thursday. The firm has a market capitalization of $9.17 million, a […]

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX – Get Free Report) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 1,030,000 shares, a growth of 19.7% from the July 15th total of 860,800 shares. Approximately 6.6% of the shares of the company are […]

AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Free Report) will announce its 6/30/2023 earnings results after the market closes on Thursday, August 10th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link. AcelRx Pharmaceuticals Price Performance Shares […]

StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a research report released on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock. AcelRx Pharmaceuticals Stock Down 3.6 % Shares of NASDAQ:ACRX opened at $1.07 on Friday. AcelRx Pharmaceuticals has a 52-week low of $0.55 and […]